Sai Life Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 7 Aug 2026

Company page: Sai Life share price, financials & guidance record

Sai Life Sciences delivered a strong Q1 FY27, with revenue growing 12% year-over-year to INR 553 crores, primarily driven by a 26% increase in CRO services. The company reaffirmed its long-term growth guidance of 15-20% revenue and 28-30% EBITDA margin, anticipating a stronger second half due to planned capacity expansions. Strategic focus remains on evolving into a multi-modality CRDMO, with significant investments in peptides, XDC, and formulation capabilities.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q1 FY27: revenue up 11.7%, net profit up 21.7% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	396	440	580	496	537 +36%	556 +26%	602 +4%	554 +12%
Expenses	293	320	422	375	392	369	426	406
EBITDA	102	120	158	121	146 +43%	188 +57%	177 +12%	148 +22%
Margin	26%	27%	27%	24%	27%	34%	29%	27%
Other income	10	9	10	10	15	0	16	4
Interest	21	23	11	12	9	10	8	8
Depreciation	36	34	37	38	40	44	45	46
Profit before tax	55	72	119	81	112 +104%	134 +86%	139 +17%	98 +21%
Tax rate	25%	25%	26%	25%	25%	25%	25%	25%
Net profit	42	54	88	60	84 +100%	100 +85%	104 +18%	73 +22%
EPS	2.17	2.59	4.24	2.90	4.00	4.75	4.92	3.45

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls